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Abstract
Objectives Self-reported progression was evaluated as a pre-
dictor of survival in patients with metastatic gastrointestinal
stromal tumor (GIST).
Methods This is a follow-up of an open cohort study of
Life Raft Group (LRG) members with a diagnosis of KIT-
positive metastatic GIST receiving imatinib from May
2000–December 2007 reporting their subjective response
to therapy by completion of an internet-based question-
naire. Subjects received ≥1 year of imatinib and reported an
initial positive response. Members reporting stable disease
or progression were excluded. Self-reported progression-
free survival (srPFS) was compared with overall survival
(OS) and analyzed by starting and last reported dose.
Results One hundred sixty-nine subjects reported a mean
starting dose of 527.8±177.9 mg/d at a mean age of 53.8±
11.6 years at initial diagnosis. Of those reporting progres-
sion, 66% died versus 11% of those not reporting progres-
sion (P<0.0001). When analyzed by last reported dose, a
median srPFS benefit of 27.3 months was observed for
the >400 mg/d group (P=0.0017). Sixty-two percent of
subjects who initiated therapy at >400 mg/d reported a dose
reduction. When analyzed by last reported dose, a signif-
icant benefit in OS (P=0.0229) and srPFS (P=0.0069) was
observed for subjects taking 600 over 400 mg/d.
Conclusions srPFS strongly correlated with OS. Signifi-
cant advantages were observed when last reported dose
was considered, as was higher daily dose. These observa-
tions suggest that careful escalation to intermediate daily
doses should be investigated further for its potential to
reduce the incidence and severity of adverse events, but
also as a strategy against developing secondary resistance
to imatinib.
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Gastrointestinal stromal tumor (GIST) is a soft tissue
sarcoma that can arise anywhere along the gastrointestinal
tract, most commonly in the stomach and small intestine.
The incidence of GIST is believed to be between six to 15
cases per million per year [1–3]. The understanding of the
biology of GIST was revolutionized by the discovery of the
roles of mutated growth factor receptor tyrosine kinases
KIT (c-KIT, CD117) [4, 5] and PDGFRα [6] in pathogen-
esis. These mutations result in the constitutive activation of
these receptors and drive the proliferation of GIST tumor
cells. Activating mutations in the KIT receptor are observed
in about 80% of GISTs and PDGFRα mutations in a further
5–10% [7]. Primary GIST tumors most frequently metas-
tasize to the peritoneum and liver [8, 9]. Cytotoxic
chemotherapy is ineffective in GIST, and until the intro-
duction of targeted therapies, the prognosis was poor, with
median survival time less than 2 years in the case of
metastatic disease [10].
Imatinib (also known as STI-571, Glivec®, or Gleevec®)
is an oral, small-molecule tyrosine kinase inhibitor (TKI)
originally developed as an inhibitor of the BCR–ABL
fusion protein for the treatment of chronic myelogenous
leukemia [11]. Imatinib also inhibits KIT activity [12, 13],
proved to be highly effective against GIST [14], and is now
the first-line treatment for advanced and metastatic disease
[9, 15–17]. Despite the success of imatinib for GIST, its ef-
fectiveness is limited by several considerations. First, patients
experience a wide variety of dose-related side effects,
including nausea, edema, cytopenias, rash, bleeding, and
severe hepatotoxicity [18]. These side effects can necessitate
dose reductions or discontinuation. Second, GIST tumors are
highly heterogeneous with respect to the mutations they
harbor[7, 19], and receptors bearing different mutations may
have very different sensitivities to inhibition by imatinib [20,
21]. GIST tumors may also not respond well initially if they
harbor mutations that are resistant to imatinib therapy
(primary resistance), and even tumors that initially respond
well may subsequently become drug-resistant (secondary
resistance), leading to tumor progression and treatment
failure [22]. This resistance may result from development/
selection of additional KIT mutations or other mechanisms
[23]. Sunitinib, a newer TKI, has recently been approved in
many countries for imatinib-resistant GIST; however, more
effective therapies for imatinib- and sunitinib-resistant GIST
are needed. A number of new tyrosine kinase-targeted
therapies are now in clinical trials for GIST.
In August 2000, the European Organization for Research
and Treatment of Cancer (EORTC) Soft Tissue and Bone
Sarcoma Group initiated a multi-national, phase I, dose-
escalation study of imatinib for patients with advanced soft
tissue sarcoma, including patients with GIST. A daily dose
of 800 mg/d (400 mg b.i.d.) was determined to be the
maximum tolerated dose [24]. In the phase II B2222 trial, a
total of 147 patients were randomized to receive either 400
(n=73) or 600 mg/d (n=74). Twenty-eight percent of
patients remained on study with a follow-up of up to
71 months [25]. A slightly longer progression-free survival
was reported in the 600 mg/d dose group than in the
400 mg/d dose group, although the result was not sta-
tistically significant (24 versus 20 months, median time to
progression, P=0.371, log-rank test). Data on dose reduc-
tions occurring during this trial have not been reported.
Two large randomized phase III trials have been
conducted that compared 400 and 800 mg/d imatinib in
advanced or metastatic GIST patients. The United States/
Canadian Intergroup S0033 trial by the National Cancer
Institute accrued 746 patients between December 2000 and
September 2001 [26]. An intent-to-treat analysis of this
study observed no significant between-group differences in
either progression-free survival (median PFS 18 and
20 months, respectively, P=0.13) or overall survival (median
overall survival 55 months and 51 months, respectively, P=
0.83). The larger phase III trial (EORTC 62005) was
conducted by the EORTC, the Soft Tissue and Bone
Sarcoma Group, the Italian Sarcoma Group, and the Austral-
asian Gastro-Intestinal Tumors Group [27]. This pivotal trial
accrued 946 patients between February 2001 and February
2002. At a median follow-up of 760 days, 56% of patients
on 400 mg/d had progressed compared with 50% on
800 mg/d (P=0.026, HR=0.82). In the study reported by
Verweij et al., 60% of the patients assigned to 800 mg
imatinib daily were subsequently reduced in dose owing to
side effects, versus 16% on 400 mg daily (P<0.0001) [27];
similar numbers were reported by Blanke et al., in the other
phase III pivotal trial [26]. Patients may also choose to take
lower (or perhaps even higher) doses than prescribed, or may
alter or interrupt their dosing schedule, all issues collectively
relating to treatment compliance [28].
Preliminary results of MetaGIST, an initial meta-analysis
of the two pivotal trials, reported in 2007, a small but
statistically significant progression-free survival benefit for
the higher dose arm (median benefit was 4 months, P=0.04);
however, there was no difference between dose groups in
overall survival, with a median overall survival of 49 months
for both (P=0.97, HR=1.00). Approximately 60% of
patients survived for 3 years [29]. A more recent meta-
analysis of these trials confirmed 400 mg/d as the recom-
mended starting dose of imatinib for metastatic and advanced
GIST patients; however, for patients who either progressed at
this standard dose or harbor an exon 9 KIT mutation, the
higher daily dose should be considered [30]. Some members
of the JNCCN task force concur with 800 mg/d of imatinib
f o rp a t i e n t sw i t hd o c u m e n t e dK I Te x o n9m u t a t i o n s ;t h i si sa
category 2B recommendation [31].
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usually performed on the basis of intent-to-treat. Patients in
these trials are analyzed as randomized, and therefore, by
their initial daily dosage groups regardless of any subse-
quent changes in treatment. Intent-to-treat analysis therefore
avoids possible confounding effects due to non-random
changes, thus preserving the randomized nature of the trial.
This simplification, however, would systematically discard
any available information regarding reported dose histories,
e.g., last observation carried forward and exposure esti-
mates, information which can potentially provide insight
into the agent’s effectiveness.
The Life Raft Group is an international, internet-based,
non-profit organization providing support, through educa-
tion and innovative research, to GIST patients and their
families. To monitor and evaluate information about treat-
ment effectiveness and side effects, the Life Raft Group has
created and maintained its own patient-driven database.
Objectives
The objectives of this study were to evaluate whether self-
reported progression was a robust predictor of survival and
how rates of progression-free and overall survival reported
in this manner correlated to imatinib dose, in patients with
metastatic GIST.
Methods
Study Design
This is an open cohort study of the effect of imatinib dosage
upon overall and self-reported progression-free survival of
metastatic gastrointestinal stromal tumor (GIST) patients
within the Life Raft Group’s member database from May
2000–December 2007. This report is a continuation of a
study of 169 subjects presented at the 2004 Connective
Tissue Oncology Society Meeting [32] in Montreal,
Canada, with a follow-up analysis from December 2007.
Setting
The Life Raft Group database contains information provided
by its members worldwide since May 8, 2000. Members were
recruited by referrals from attending physiciansor other GIST
patients; however, the majority of members were acquired
through patient-initiated contacts, following internet searches
or other requests for information and assistance. All members
had a reported diagnosis of KIT (CD117)-positive GIST.
There were no other criteria for membership, and no one was
excluded owing to age, confirmation of diagnosis, disease
status, or prior or current treatment regimen or response.
Agreeing to supply the Life Raft Group (LRG) with data was
part of the initial membership agreement; however, there was
no change in membership or status upon withdrawal of
participation. All data were collected using an electronic
questionnaire periodically forwarded as reminders to mem-
bers, a relative, or a caregiver. Data fields collected included
dates of diagnosis, initiation of imatinib treatment and last
update, initial and last reported daily dosages, and response to
treatment. Demographic data included sex, date of birth,
country, and primary tumor site. Outcomes were based upon
subjective status in response to imatinib therapy: no evident
disease (NED), shrinkage, progression, stable disease, or
deceased.Responseswerereviewed,andthedatawerelogged
and curated by LRG staff who confirmed all end points, e.g.,
death or progression.
Selection and Description of Study Participants
All subjects included within this study had a diagnosis of
KIT-positive metastatic GIST and had initiated imatinib
therapy at least 1 year prior to inclusion.
In order to select for subjects who might receive the
greatest benefit, only members who reported initial tumor
response (“shrinkage”) to imatinib therapy and remained
progression-free for at least 1 year were included. In
addition, members who reported only stable disease (“no
shrinkage”) throughout this first year were excluded. These
criteria were intended to select for subjects who were most
likely to benefit from imatinib by excluding those who
might harbor a mutation associated with primary resistance
to the drug.
Treatment interruptions and decreases in dosage were
permitted within the first year to manage adverse events,
and dose increases were also permitted for reasons other
than disease progression. There were no additional patient-
or disease-specific exclusion criteria, nor any restrictions on
comorbid conditions or polypharmacy.
All treatment decisions were at the discretion of the
treating physician; however, 47 of the included subjects
reported being enrolled in a clinical trial of imatinib for the
treatment of metastatic or advanced GIST (phase II, B2222
[25]; phase III, EORTC 62005 [27], S0033 [26]). The
starting imatinib dosages for these subjects would have
been initially assigned at random and subsequent treatment
decisions made according to their respective trial protocols.
Outcomes and End Points
Owing to the open, observational, and exploratory nature of
this study, overall survival was selected as the primary
outcome, with self-reported progression-free survival as a
secondary parameter. Demographic, disease, and treatment
details were obtained at membership registration, and
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basis. Updates were expected to coincide most often with
specific, unambiguous events including periodic CAT
scans, the onset/resolution of adverse events, and the
consequent physician-directed interruptions, or other treat-
ment regimen adjustments, as well as end points. End
points included tumor progression, termination of imatinib
therapy for reasons other than progression, and death.
Subjects were followed from registration until September
2004, in the initial analysis and again in December 2007, in
this follow-up analysis.
Statistical Analyses
Survival analysis using a log-rank (Mantel–Cox) test was
performed using GraphPad Prism (version 5.01, for
Windows, GraphPad Software, San Diego, CA, USA,
www.graphpad.com). Two-sided P value<0.05 was consid-
ered significant. Hazard ratios were computed by the
Mantel–Haenszel method also using GraphPad Prism. All
other calculations were carried out using Microsoft Excel
2004 for Mac (version 11.5.4).
Results
Participant and Disease Characteristics
The study analyzed 169 subjects with metastatic GIST who
had been treated with imatinib for an average of 4.7
(1.6 SD) years. The population contained 92 males and 77
females from 17 countries at a mean age of 53.8 (11.6 SD)
years at initial diagnosis (Table 1).
Location of primary tumor was provided as free text and
sites were grouped post hoc as: upper/mid-GI (esophagus,
stomach, abdomen, omentum), bowel (small intestine,
colon, rectum), other (liver, bladder, pancreas), or unknown
(Table 2). Half (51%) of all reported primary tumors were
located within the upper- to mid-gastrointestinal tract;
however, the majority were situated in either the stomach
(n=60) or abdomen (n=20), and there were no reported
cases of an esophageal site. “Bowel” was a composite of
mostly small intestinal tumors (n=53) with few colon (n=
6) or rectal (n=2) tumors. There were four reported liver
tumors, six cases of unspecified “other” location, and nine
reported primary tumors of unknown location. Other
subject and disease characteristics are reported in Table 3.
Mutationaldata were provided for only 15% (26 of 169) of
the subjects, too low for meaningful analysis. Of the 26
patients with mutational data, one was wild-type GIST, four
hadKITexon9mutations,20hadKITexon11mutations,and
one had a PDGFRα mutation within an unspecified exon.
Subjects reported taking an average initial daily dosage
of 572.8 mg (177.9 SD) of imatinib. At the time of follow-
up analysis, subjects last reported taking an average daily
dosage of 455.0 mg/d (161.0 SD) of imatinib with a mean
exposure of 30.2 (8.9 SD) months.
Self-Reported Progression as a Surrogate for Survival
in Metastatic GIST
Since the validity of patient-reported progression had not
previously been established, members who reported no
progression (n=91) by October 2004 were compared with
those who reported progression (n=44). Of the 78 subjects
who had reported progression by October 2004, 29 had
died by December 2007 and 15 were still alive. The 34
subjects who had died by 2004 were excluded. Of those
reporting progression in 2004, 29 of 44 (66%) died before
the second analysis (Dec 2007) compared with ten of 91
Total LRG database
(2000–2004)
N=482
(325 with metastatic disease in 2004)
⇓
Metastatic patients on imatinib for ≥1year
N=252
⟹ Excluded owing to: Males Females
⇓ Progression in first year 7 3
(83 members excluded) Stable disease 14 11
Insufficient data 23 25
Patients at 1 year with reported shrinkage and NED only Males Females
⇓ n≤400 mg/d 52 48
N=169 ⟹ 400 < n < 800 mg=d 13 13
n≥800 mg/d 27 16
Table 1 Selection of study sub-
jects and data acquired from
LRG members
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0.0001, HR=17.46; Fig. 1). As of December 2007, a total of
81% (63 of 78 subjects) of those who reported tumor
progression by Oct 2004 died versus 11% (ten of 91 subjects)
for those who had not reported progression by 2004.
Imatinib Dose Changes
Dosage changes and last reported status are summarized in
Table 4. Of the 69 subjects who began treatment in the high-
dose group (>400 mg/d), 43% had dose reductions that
moved them into the low-dose (≤400 mg/d) group, and 19%
had dose reductions but remained in the range of the high-
dose group when last reported dose was considered; 38% had
no dose reductions (Table 5). Of those subjects who initiated
treatment in the low-dose group, 14 (14%) had dose increases
that moved them into the high-dose group prior to progres-
sion using last reported dose. Nine percent of the subjects that
started on ≤400 mg/d required a dose reduction.
Males were better able to tolerate higher imatinib doses
than females (Table 6). Nineteen percent of females who
started at 800 mg/d remained at this highest daily dose.
However, despite their relatively greater tolerance, only
26% of males who started on 800 mg/d remained at this
dose. Eighty-five percent of males and 38% of females who
began at 600 mg/d remained at that level.
Evaluation of Overall Survival, High- Versus
Low-Dose Imatinib
In an analysis of overall survival by starting imatinib dose,
a small benefit of 5.7 months was observed for the high-
over low-dose group and did not reach statistical signifi-
cance (77 versus 71.3 months, P=0.336, HR=1.25; Fig. 2).
When the analysis was repeated using last reported dose, a
statistically significant benefit in overall survival was
observed for the higher dose group. The median survival
was 70.8 months for the low-dose group and had not yet
been reached for the high-dose group (P=0.037, HR=1.66;
Fig. 3).
Evaluation of Self-Reported Progression-Free Survival,
High- Versus Low-Dose Imatinib
In analyzing the progression-free survival of subjects
categorized by starting daily dose of imatinib, a 7.7 month
median benefit in srPFS was observed for the high-dose
group that did not reach significance (P=0.1029, Fig. 4). In
contrast, using last reported dose, the median srPFS was
27.3 months longer in the high-dose group (58.8 versus
31.5 months, P=0.0017, HR=1.826; Fig. 5).
Effectiveness of Imatinib, 600 mg/day
Because the 800 mg/d dose was not tolerated well by
persons of either sex, the effectiveness of 600 mg/d, as well
as the difference in effectiveness between 600 and 800 mg/d
was evaluated by last reported dose. We compared subjects
taking 400 mg/d (n=98) to those taking 600 mg/d (n=36).
In addition, we compared subjects on 600 mg/d directly to
those on 800 mg/d (n=15). However, the comparison of
600 to 800 mg/d should be viewed with caution due to the
small size of the 800 mg/d group.
Overall Survival, 600 mg/day
Subjects who last reported taking 600 mg/d showed a
statistically significant survival advantage over those last
reported taking 400 mg/d (P=0.0229, HR=1.877; Fig. 6).
For comparison, the hazard ratio for overall survival
comparing low (≤400 mg/d) to high (>400 mg/d) doses
was 1.663 (P=0.037; Fig. 3). The small advantage for the
Table 2 Patient and disease characteristics: included subjects and
remaining members
Study
population
(N=169)
Remaining
members
(N=313)
Median age (range) at imatinib
start in years
54 (21–86) 53 (8–85)
Males 92 (54%) 163 (52%)
Continent
The Americas
a 145 (86%) 256 (82%)
US 133 (79%) 240 (77%)
Europe 16 (9%) 29 (9%)
Asia 4 (2%) 9 (3%)
Africa 1 (0.6%) 1 (0.3%)
Oceania 1 (0.6%) 4 (1%)
Unknown 2 (1%) 14 (4%)
Primary tumor site
b
Upper-/mid-GI 86 (51%) 157 (50%)
Bowel 64 (38%) 111 (35%)
Other 10 (6%) 18 (6%)
Unknown 9 (5%) 27 (9%)
Clinical trial participants 47 (28%) 21 (7%)
Starting dose (mg/d)
Median (range) 400 (0–800) 400 (100–800)
Mean (SD) 527.8 (177.9) 424.8 (205.7)
aMembers located in the Americas were almost exclusively in N.
America. There was a single member in Costa Rica that was not
included in the study and a single study subject in Mexico; no
members were in S. America
bPrimary tumor sites were grouped post hoc as: upper-/mid-GI
(esophagus, stomach, abdomen, omentum), bowel (small intestine,
colon, rectum), other (liver, bladder, pancreas), and unknown
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subjects on 800 mg/d, was not statistically significant. The
median overall survival was 70.8 months for the entire low-
dose group (≤400 mg/d) and 67.8 months for patients
taking 400 mg/d only (excluding those taking <400 mg/d).
The median overall survival had not been reached for either
the entire high-dose group or subjects taking 600 mg/d
(Figs. 3 and 6). No significant difference in overall survival
was observed between subjects last reporting a daily dosage
of 600 (n=36) or 800 mg/d (n=15) of imatinib (P=0.75,
HR=0.8466).
Self-Reported Progression-Free Survival, 600 mg/day
In an analysis of last reported dose, a significantly longer
srPFS was observed for 600 over 400 mg/d imatinib.
Subjects last reportedly taking 400 mg/d (n=98) had a
median srPFS of 30.2 months compared with 58.6 months
srPFS for subjects taking 600 mg/d imatinib (n=36), a
benefit of 28.4 months for the latter group (P=0.0069, HR=
1.811; Fig. 7). In addition, the median srPFS for patients
taking 600 mg/d was almost identical to that for the entire
high-dose group (>400 mg/d), 58.6 months and
58.8 months, respectively. There was no significant
difference in srPFS between patients taking 800 (n=15)
and 600 mg/d of imatinib (n=36; data not shown).
Survival by Gender
In contrast to the entire sample of patients, overall survival
by gender did not show a statistically significant benefit.
Median overall survival for females in the low-dose group
was 70.8 months and had not yet been reached in the high-
dose group at the time of follow-up analysis. The hazard
ratio was 1.88. The median overall survival times for males
in the low- and high-dose group were 74.9 and 77.0 months,
respectively (P=0.087,HR=1.70). In a 400 versus 600 mg/d
comparison of last reported dose, the median overall survival
for females on 400 mg/d was 68.9 months and had not yet
been reached in the 600 mg/d group (P=0.079, HR=2.31).
For males with a last reported daily dose of 400 mg/d, the
median overall survival was 60.2 months and had also yet to
be reached at end point for those taking 600 mg/d (P=0.096,
HR=1.783).
When last reported dose was used to evaluate srPFS,
both males and females showed a benefit from reportedly
higher doses of imatinib. The median srPFS for males was
29 months in the low-dose group and 49.3 months in the
high-dose group, a benefit for of 20.3 months (P=0.017,
HR=1.83). The median srPFS for females was 37.5 months
in the low-dose group and had not been reached in the high-
dose group (P=0.023, HR=2.04). In a 400 versus 600 mg/d
comparison, median srPFS time for females on a last
Number of subjects n≤400mg/day 400 < n < 800 ≥800mg/day
Sex
Males 52 13 27
Females 48 13 16
Continent
N. America 83 25 37
Europe 10 0 6
Asia 4 0 0
Africa 1 0 0
Oceania 1 0 0
Unknown 1 1 0
Primary tumor site
a
Upper-/mid-GI 50 11 25
Bowels 36 11 17
Other 8 1 1
Unknown 6 3 0
Clinical trial participants 21 9 17
Mean age at diagnosis in years (SD) 55.8 (12.2) 50.3 (10.1) 51.1 (10.3)
Minimum to maximum 28.2–86.4 21.0–71.9 31.0–74.9
Mean age at study start in years (SD) 59.4 (12.2) 54.9 (10.4) 55.7 (10.4)
Minimum to maximum 32.9–90.1 23.0–76.0 37.3–78.3
Mean imatinib exposure in years (SD) 4.6 (1.6) 4.9 (1.7) 4.9 (1.6)
Minimum to maximum 0.9–7.1 1.8–7.3 1.1–6.8
Table 3 Subject and disease
characteristics by starting imati-
nib dosage group
aPrimary tumor sites were
grouped post hoc as: upper-/
mid-GI (esophagus, stomach,
abdomen, omentum), bowel
(small intestine, colon, rectum),
other (liver, bladder, pancreas),
and unknown.
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not been reached in the high-dose group (P=0.0357, HR=
2.187). The median srPFS times for males on a last reported
dose of 400 versus 600 mg/d were 25.9 and 49.3 months,
respectively, a difference that was near the borderline of
statistical significance (P=0.0505, HR=1.722).
Discussion
The utility of patient-reported tumor progression at last
reported dose as a surrogate for survival in metastatic GIST
patients was investigated, based on analysis of an internet-
driven open cohort study of members of the Life Raft
Group who completed a self-reported subjective assessment
of progression-free survival compared against overall
survival. Excluding members who had died by the initial
analysis, subjects who had reported stability by 2004 were
far more likely to be alive in 2007 than those who reported
progression at that time (P<0.0001, HR=17.46).
LRG members demonstrated a clear advantage at higher
daily doses of imatinib in terms of both overall and
progression-free survival, when last reported dose was
considered. These advantages no longer reached signifi-
cance when analyzed by prescribed initiating dose. Recog-
nizing that many of the potential side effects from imatinib
therapy improve over time [27], careful dose-escalation
strategies may be considered to increase imatinib tolerabil-
ity, and hence treatment compliance, and reduce the risk of
developing secondary resistance to the drug. This analysis
of member-supplied data also suggests that 600 mg/d may
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Fig. 1 Overall survival comparison of those reporting progression by
2004 versus those who did not
Table 4 Schedule of dosage changes and last reported status at end
point
Dose changes (mg/day)
Starting dosage End point
dosage
Progression No
progression
Total
100 400 1 1
200 600 1 1
300 250 1 1
300 1 1
400 1 1
400 0 2 2 4
300 4 1 5
400 57 16 73
600 5 6 11
800 1 1 2
≤400 subtotal 72 28 100
600 300 2 1 3
400 4 2 6
500 1 1
600 7 7 14
800 2 2
600 subtotal 13 13 26
800 0 2 2
100 1 1
400 13 5 18
450 1 1
500 1 1
600 6 4 10
800 6 4 10
800 subtotal 30 13 43
Grand total 115 54 169
Progression includes subjects who reported either tumor progression
or death at last follow-up. No progression includes a last report of no
evident disease, tumor shrinkage, and stable disease
Dose reduced to n (%)
400 mg/d 30 (43)
450–600 mg/d 13 (19)
Total dose reductions 43 (62)
No dose reduction 26 (38)
Table 5 Dose reductions in the
starting high-dose group (n=69
at >400 mg/d)
Table 6 Imatinib dose reductions by gender and starting dose
Gender/starting dose Start (n) End point, n
(% remaining)
Female
400 mg/d 44 38 (86)
600 mg/d 13 5 (38)
800 mg/d 16 3 (19)
Male
400 mg/d 51 48 (94)
600 mg/d 13 11 (85)
800 mg/d 27 7 (26)
66 J Gastrointest Canc (2010) 41:60–70be as effective as 800 mg/d of imatinib. However, due to
the small number of subjects initially prescribed the highest
daily dose, only a qualitative comparison should be made.
The data presented here suggest that higher daily doses
of imatinib reduce rates of progression. In spite of this fact,
higher doses may not be appropriate for all patients with
metastatic GIST. For patients taking the same dose of
imatinib, plasma levels can vary by 4-fold or more [33, 34].
Side effects from imatinib also vary significantly, from very
mild to life threatening and even fatal [26]. Most side
effects are dose-dependent and thus both more likely and
more severe at higher doses [18]. It is also important to note
that there were some long-term responders in the low-dose
group, including some patients taking as little as 300 mg/d.
Fewer females than males were able to tolerate the higher
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J Gastrointest Canc (2010) 41:60–70 67doses of imatinib, which suggests that females may benefit
from more careful dose-escalation strategies. Since side
effects can improve over time, the utilization of supportive
medical interventions to directly manage these events may
prove invaluable in the ongoing development of treatment
strategies.
Subjects who developed imatinib resistance over the
course of treatment had much higher mortality rates than
those that remained stable, despite crossover to higher
doses or other treatments. This population was initially
analyzed in October 2004, at which time 91 reported stable
disease on imatinib therapy but 78 had reported progres-
sion, of whom 34 had died by November 1, 2004. Those
who progressed moved to various other treatment regimes,
often through several treatment strategies. Sixty percent of
those on a lower initial dose of imatinib crossed over to a
higher dose; 65% were given sunitinib (SU11248, Sutent®);
41% underwent surgery, and 12% received nilotinib
(AMN107, Tasigna®).
Despite these subsequent treatments, the mortality rate
among those who had progressed by October 2004 was
81% by December 2007, compared with a mortality rate of
11% among those who reported stable disease in October
2004. Seventy-two percent of these deaths occurred within
2 years from the point of relapse.
A recent meta-analysis of the two pivotal phase III trials
of imatinib for unresectable or metastatic GIST confirmed a
typical initial starting daily dose of 400 mg/d. A dose of
800 mg/d was found to benefit those patients with exon 9
KIT mutations and those who progressed at the standard,
starting dose of 400 mg/d [30]. In addition, preliminary
data based upon imatinib plasma levels from 73 of the 147
patients enrolled in the phase II B2222 trial suggested that
at least 25% of these GIST patients were under-dosed [35].
In the EORTC pharmacokinetic (PK) study, clearance of
imatinib increased by 33% in GIST patients in the 12-month
period studied. This study found a 42% decrease in area
under the curve over the 12 months. While the EORTC PK
study was not conclusive, it adds to the concern that patients
treated with lower doses of imatinib might be at higher risk
of developing resistance.
At least three different theories have been proposed to
explain this phenomenon: (1) Imatinib clearance increases
over time, possibly related to improved liver function [36].
(2) Multi-drug resistance transport proteins are induced
over time, decreasing the net transport of imatinib across
the intestinal membrane [37]. (3) Patient adherence to the
drug falls off over time [28].
The results of this analysis show a strong correlation
between imatinib treatment failure and lower survival and
suggest that the avoidance of developing resistance may
yield better outcomes than overcoming secondary resis-
tance. However, only a clinical trial will be able to resolve
the question of whether dose-escalation or other strategies
(possibly including measuring imatinib plasma levels)
would produce superior results to the currently recommen-
ded dose of 400 mg/d.
This analysis of patient-reported progression at last
reported dose offers a real-world complementary perspec-
tive to that seen in investigator-initiated randomized trials.
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68 J Gastrointest Canc (2010) 41:60–70While there is no substitute for hypothesis-driven clinical
research, given the relative ease, flexibility, and expense of
collecting observational data, such investigations should be
encouraged as possible hypothesis-generating resources
towards improvements in care.
Limitations
Due to its relatively small size and non-randomized nature,
care must be taken when interpreting the results of this
study. In terms of study design and the potential for
selection bias, the LRG members captured in this analysis
may not be representative of the entire population of GIST
patients. In order to address this concern, every attempt has
been made to compare the characteristics of both the
included and excluded LRG member populations, with the
underlying assumption that the event of seeking LRG
membership initially was itself effectively at random.
Excluding members who progressed during the first year
or who did not show initial shrinkage effectively eliminated
those with primary resistance. These exclusion criteria may
have also eliminated a higher proportion of KIT exon 9
primary mutations, biasing the results towards increased
median survival rates compared with other studies that
include this population. One such study indicated that exon
9 patients receive a greater benefit from higher doses of
imatinib [38]. This study indicates that the same may be
true for other GIST genotypes as well. These criteria may
have also selected for healthier patients who are more likely
to be able to tolerate higher doses of imatinib and may have
fared better regardless of dose, initial or last reported. In
addition, as all members reported their own daily dosages,
this study was not controlled in any fashion, and known
dosages, both low and high, could have influenced the
subjective reporting of disease progression.
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